Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

13 de novembro de 2026 atualizado por: Regeneron Pharmaceuticals

A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors

This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).

The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body reacts to the study drug, in a way that may cause the study drug to not work as well
  • What is the best dose of the study drug for treating previously treated, advanced solid tumors

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

320

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • North Carolina
      • Huntersville, North Carolina, Estados Unidos, 28078
        • Recrutamento
        • Carolina BioOncology Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  1. Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
  2. Participants must not be candidates for curative surgery or radiation
  3. Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
  4. Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
  5. At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
  2. Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
  3. Has undergone major surgery within the 14 days prior to first administration of study intervention
  4. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
  5. Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
  7. Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

Note: Other protocol defined inclusion/ exclusion criteria apply

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Parte 1: Escalonamento de Dose

Administered per the protocol

Experimental: Parte 2: Expansão da Dose

Administered per the protocol

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Occurrence of dose-limiting toxicities (DLTs)
Prazo: Up to 21 days

Part 1 (Dose Escalation)

Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Objective response (investigator assessed) per RECIST 1.1
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Concentrations of ADC
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of total antibody
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of payload (ProDXd and DXd)
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Magnitude of ADA against REGN13089-M404-M2980
Prazo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Duration of response per RECIST 1.1
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Time to response per RECIST 1.1
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Progression-free survival per RECIST 1.1
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Overall survival
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of TEAEs considered clinically significant
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Laboratory abnormalities considered clinically significant
Prazo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Clinical Trial Management, Regeneron Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de outubro de 2026

Conclusão Primária (Estimado)

10 de março de 2031

Conclusão do estudo (Estimado)

10 de março de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

2 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de outubro de 2026

Primeira postagem (Real)

7 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • R13089-ONC-25128

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Prazo de Compartilhamento de IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Critérios de acesso de compartilhamento IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever